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Background: Hemoglobin (Hgb) concentration at diagnosis is associated with outcome in
cancer. In a recently reported simplified 3-factor prognostic score in Hodgkin lymphoma,
Hgb, along with age and clinical stage, outperformed the classical International Prognostic
Score with seven parameters.
Methods: In the present study, we investigated if pretherapeutic Hgb concentration added
prognostic information to the NCCN-IPI in diffuse large B-cell lymphoma. We included
patients from the Danish Lymphoma Registry (LYFO; N = 3499) and from the Molecular
Epidemiology Resource (MER; N = 1225), Mayo Clinic and University of Iowa. Four sex-
specific Hgb groups were defined: below transfusion threshold, from transfusion threshold to
below lower limit of normal, from lower limit of normal to the population mean, and above
the mean. We used multivariable Cox regression to estimate the hazard rate ratios (HR) and
95% CIs for overall survival (OS) and event-free survival (EFS), adjusting for sex, NCCN-
IPI, comorbidity, and rituximab treatment.
Results: Approximately half of the patients had Hgb levels below the lower limit of normal.
Compared to patients with Hgb levels above the mean, an inferior OS was directly correlated
with lower pretreatment Hgb within the predefined groups (HR=1.23, HR=1.51, and
HR=2.05, respectively). These findings were validated in the MER.
Conclusion: Based on multivariable analysis, lower pretreatment Hgb, even within the
normal range but below the mean, added prognostic information to established indices such
as the NCCN-IPI and the Charlson comorbidity index.
Keywords: diffuse large B-cell lymphoma, hemoglobin, prognosis, NCCN-IPI
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malignancy
among adults.1 It is primarily a disease of the elderly but it occurs in all age groups and
extranodal involvement is present in up to a third of the cases.1,2 At the time of diagnosis,
almost half of patients withDLBCL have a hemoglobin (Hgb) concentration fulfilling the
definition of anemia.3–7 Anemia is associated with decreased life expectancy in many
cancers.8 Pretreatment anemia is included as an adverse factor in prognostic indices for
lymphoid malignancies other than DLBCL, e.g., the International Prognostic Score for
advanced Hodgkin lymphoma (IPS) and the Follicular Lymphoma International
Prognostic Index (FLIPI).9,10 Notably, the prognostic importance of anemia was not
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examined in the large international patient cohorts used to
establish the International Prognostic Index (IPI) or the sub-
sequent National Comprehensive Cancer Network
International Prognostic Index (NCCN-IPI) developed to
reflect the introduction of rituximab in the first-line treatment
of DLBCL.11,12 Anemia has previously been associated with
features of high-risk disease in DLBCL such as bone marrow
infiltration and elevated lactate dehydrogenase (LDH).3,4 A
possible prognostic relevance of Hgb levels in newly diag-
nosed patients with DLBCL may be clinically useful in order
to improve risk-adaptedmanagement strategies. Therefore, we
investigated the impact of pretreatment Hgb levels on the
prognosis of newly diagnosed DLBCL patients treated with
anthracycline-containing regimens and validated our findings
in an independent cohort from the USA.
Methods
Data from two registries with prospective inclusion of
DLBCL patients were used for this study. For discovery,
we used the Danish Lymphoma Registry (LYFO).
Discovery Cohort - LYFO
This study was approved by the Danish Data Protection
Agency (1-16-02-562-13) and the Danish Health and
Medicines Authority (3-3013-1079/1/).
Patients registered in the LYFO with DLBCL between
January 1, 2000, and December 31, 2012, were included if
they were registered with a diagnosis of de novo DLBCL
(patients had neither a past diagnosis of indolent lymphoma
or composite/discordant lymphoma), did not have primary
CNS-lymphoma, and had received anthracycline-containing
chemotherapy with or without the addition of rituximab. The
International Classification of Disease for Oncology, third
edition histology codes (ICD-O-3) for DLBCL (9680), was
used to identify all patients with DLBCL. The LYFO registry
prospectively includes all patients with lymphoid malignan-
cies referred to hematology departments in Denmark and has
had nationwide coverage since 2000.13 Recently, LYFO was
described to include 98% of all lymphomas in Denmark with a
completeness of registered variables of 99% and positive
predictive values for variables ranging from 88% to 99%.14
Treatment data are registered according to the type of chemo-
and immunotherapy, date of start and end of treatment, and the
number of treatment courses administered.14 In the present
study, chemotherapy regimens included were: CHOP (cyclo-
phosphamide, doxorubicin, vincristine, prednisone), CHOEP
(cyclophosphamide, doxorubicin, etoposide, vincristine, pre-
dnisone), and more intensive anthracycline-containing
regimens. In order to maximize the completeness of treatment
data, we combined the information contained in the LYFO
registry with treatment information from the Danish National
Patient Registry (DNPR). The DNPR is an administrative
register that contains individual data on diagnoses, treatments,
and time periods for each contact with the public health care
system.15 Pathology reports of the primary as well as the
relapse biopsies were retrieved from the Danish National
Pathology Registry, which contains detailed descriptions of
all pathology specimens analyzed in Denmark since 1997.16
Exposures
Values of pretreatment Hgb and LDH were collected from
regional laboratory systems of the five administrative
health regions of Denmark.17 For two regions, all labora-
tory measurements were retrieved from a common clinical
laboratory information database. For the remaining three
regions, laboratory data were obtained directly from the
departments of clinical biochemistry of the treating cen-
ters. We categorized Hgb levels according to four sex-
specific Hgb groups (in g/L for males, females) as below
the transfusion threshold (<98, <98), from transfusion
threshold to below lower limit of normal (98–133,
98–117), from lower limit of normal to the population
mean (134–149, 118–134), and above the mean (>149,
>134).18,19 If more than one value of Hgb was registered
in the time frame between 14 days prior to the diagnostic
biopsy and the date of treatment start, we used the lowest
of these values. This was done in order to minimize the
risk of misclassifying patients to a higher pretreatment
Hgb subgroup due to blood transfusion.
Covariates
The NCCN-IPI categories were calculated as described in
the original publication with a score of 0–1 for low, 2–3
low-intermediate, 4–5 high-intermediate, and ≥6 for high
risk.12 A Charlson comorbidity index (CCI) was computed
based on diagnoses recorded for the individual patient in
the DNPR up to 10 years prior to the date of DLBCL
diagnosis.20,21 We used the same 19 diagnoses as in the
original CCI publication and defined three levels of
comorbidity: CCI score 0 (no comorbidity), 1–2 (moder-
ate), or >2 (severe).20 The use of DNPR data to estimate
comorbidity has previously been validated for the time
period covering this study.22
Data on vital status (dead/alive) were obtained by link-
ing the LYFO registry to The Danish Civil Registration
System, which contains daily updated vital status on all
Clausen et al Dovepress
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Danish citizens. This register operates through a unique 10-
digit personal identification number and contains several
demographic parameters thoroughly described in a previous
report.23
Validation Cohort – MER
From the Molecular Epidemiology Resource (MER), we
obtained data on DLBCL patients to validate our findings.
This study was reviewed and approved by the human sub-
ject’s institutional review boards at the Mayo Clinic and the
University of Iowa. Written informed consent was obtained
from all participants. Briefly, consecutive patients with
newly diagnosed lymphoma were prospectively enrolled
from 2002 to 2015; for this analysis, we included DLBCL
patients enrolled through 2013 who were treated with an
anthracycline-based immunochemotherapy regimen.24,25
Patients with primary CNS lymphoma, posttransplant lym-
phoproliferative disorders, and primary mediastinal B-cell
lymphoma were excluded. Baseline clinical, laboratory, and
treatment data were abstracted from medical records by
using a standard protocol. Disease progression/relapse,
retreatment, and death were prospectively collected and
validated by medical record review. Event-free survival
(EFS) was defined as the time from the date of diagnosis
(date from the first biopsy specimen containing lymphoma)
to disease progression, retreatment, or death due to any
cause. Cell of origin (COO) was determined from clinical
results based on the Hans algorithm.26
Statistics
Patient baseline characteristics were presented as propor-
tions for categorical variables and as a range with median
and interquartile range (IQR) for continuous variables.
Overall survival (OS) was calculated from the date of
primary biopsy to the date of death or end of follow-up
(February 18, 2016) and EFS was calculated from primary
biopsy to the date of progression, death or last follow-up.
We used Kaplan–Meier curves and Cox proportional
hazard regression to assess the association of Hgb levels
with OS and EFS.27,28 Cox models were adjusted for
NCCN-IPI, rituximab treatment (LYFO only), sex, and
level of comorbidity. We also conducted analyses stratified
by sex, age, treatment, and NCCN-IPI (grouped as low and
low-intermediate risk vs high-intermediate and high risk).
The proportional hazard assumption was evaluated graphi-
cally with log minus log plots and was accepted. To
evaluate for nonlinear associations of Hgb levels with
OS, we used a restricted cubic spline with knots at the
Hgb percentiles 5, 17.5, 50, 67.5, and 95 and stratified by
sex.29 As a reference, we used the mean Hgb value for the
Scandinavian background population reported by three
previous studies.18,19,30 Only patients with available Hgb
values were included in the discovery analysis. In a sepa-
rate analysis, we used multiple imputation to account for
missing values for Hgb or NCCN-IPI parameters. This
was performed using chained equations under the assump-
tion that data were missing at random.31
For validation in the MER, we used MER-specific Hgb
cut-points and presented KM curves and Cox models, both
unadjusted and adjusted for sex, NCCN-IPI and comorbidity
(none vs any). All estimates were presented with 95% CI.
Statistical analyses were done using Stata14 (Stata
Statistical Software: Release 14.2 College Station, TX:
StataCorp LP). We used the STROBE and RECORD
statements to guide our report of the study.32,33
Results
Discovery
Through the LYFO registry, we identified 4765 patients
with DLBCL and 3499 fulfilled the inclusion criteria for
the analysis. Figure S1 shows the algorithm leading to the
study cohort. Baseline demographic characteristics are
summarized in Table 1. The median age at diagnosis was
65 years (range 15–95; IQR 56–73) and the majority of the
patients were men (56%). Regarding the NCCN-IPI, 424
patients (12.1%) had a low, 1382 (39.5%) a low-intermedi-
ate, 1216 (34.8%) a high-intermediate, and 422 (12.1%) a
high-risk NCCN-IPI profile. The majority of patients
received a combination of rituximab and CHOP/CHOP-
like chemotherapy 2615 (75%).
At diagnosis, anemia was present in 1612 (46%)
patients, with 1246 (36%) in the range from the transfusion
threshold to the lower limit of normal and 366 (11%) below
the transfusion threshold. Lower pretreatment Hgb levels
were associated with older age, male sex, advanced clinical
stage, extranodal disease, bone marrow infiltration, high
LDH, PS ≥2, higher NCCN-IPI score, and higher CCI.
Anemia was more frequent in men (Table 1, Figure S2A
and B); although there was no difference in the frequency of
bone marrow infiltration among sexes, neither overall (15%
men vs 14% women) nor within the two anemia subsets,
i.e., “below transfusion threshold” (31% men vs 28%
women) and “between transfusion threshold and lower
limit of normal” (19% men vs 20% women).
Dovepress Clausen et al
Clinical Epidemiology 2019:11 submit your manuscript | www.dovepress.com
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Table 1 Clinical Features And Treatment Background According To Pretreatment Hgb Subgroups (Discovery Cohort)
>149/134a 134-149/118-133 98-133/98-117b <98 Total
Age, median (range), years 62 (19-88) 65 (15-93) 66 (16-95) 67 (19-88) 65 (15-95)
Age group No. (%) No. (%) No. (%) No. (%) No. (%)
<41 years 68 (9) 81 (7) 85 (7) 18 (5) 252 (7)
41-60 266 (35) 351 (31) 332 (27) 89 (24) 1038 (30)
61-75 321 (43) 482 (43) 565 (45) 176 (48) 1544 (44)
>75 years 100 (13) 218 (19) 264 (21) 83 (23) 665 (19)
Sex
Female 395 (52) 564 (50) 407 (33) 176 (48) 1542 (44)
Male 360 (48) 568 (50) 839 (67) 190 (52) 1957 (56)
Ann Arbor stage
I - II 478 (63) 576 (51) 388 (31) 79 (22) 1521 (43)
III-IV 277 (37) 556 (49) 858 (69) 287 (78) 1978 (57)
High risk extra nodal disease
Not present 624 (83) 819 (72) 677 (54) 146 (40) 2266 (65)
Present 131 (17) 313 (28) 562 (45) 217 (59) 1223 (35)
Missing 0 (0) 0 (0) 7 (1) 3 (1) 10 (<1)
Bone marrow
No 707 (94) 1016 (90) 1002 (80) 259 (71) 2984 (85)
Yes 48 (6) 116 (10) 240 (19) 107 (29) 511 (15)
Missing 0 (0) 0 (0) 4 (<1) 0 (0) 4 (<1)
Level of LDH above
LDH-R ≤1 503 (67) 620 (55) 415 (33) 84 (23) 1622 (46)
LDH-R >1-3 218 (29) 442 (39) 662 (53) 211 (58) 1533 (44)
LDH-R >3 19 (3) 45 (4) 146 (12) 65 (18) 275 (8)
Missing 15 (2) 25 (2) 23 (2) 6 (2) 69 (2)
Performance Status
PS 0-1 710 (94) 1002 (89) 896 (72) 201 (55) 2809 (80)
PS >1 42 (6) 126 (11) 341 (27) 158 (43) 667 (19)
Missing 3 (<1) 4 (<1) 9 (1) 7 (2) 23 (1)
NCCN risk groups
Low risk 180 (24) 161 (14) 50 (4) 9 (2) 400 (11)
Low–Intermediate risk 387 (51) 518 (46) 403 (32) 57 (16) 1365 (39)
High-Intermediate risk 143 (19) 362 (32) 568 (46) 184 (50) 1257 (36)
High risk 29 (4) 62 (5) 190 (15) 105 (29) 386 (11)
Missing 16 (2) 29 (3) 35 (3) 11 (3) 91 (3)
Rituximab treatment
no 207 (27) 284 (25) 293 (24) 99 (27) 883 (25)
yes 548 (73) 848 (75) 953 (76) 267 (73) 2616 (75)
Comorbidity (CCI)
No comorbidity (0) 523 (69) 659 (58) 648 (52) 189 (52) 2019 (58)
Moderate comorbidity (1-2) 189 (25) 334 (30) 413 (33) 120 (33) 1056 (30)
Severe comorbidity (>2) 43 (6) 139 (12) 185 (15) 57 (16) 424 (12)
Total 755 (100) 1132 (100) 1246 (100) 366 (100) 3499 (100)
Notes: aHgb cutoff value for men/Hgb cutoff value for women, bHgb range for men/Hgb range for women.
Abbreviations: Hgb, pretreatment hemoglobin; NCCN-IPI, National Comprehensive Cancer Network International Prognostic Index; CCI, Charlson comorbidity index.
High-risk extranodal disease; presence of extranodal lymphomatous involvement in bone marrow, CNS, liver/GI tract, or lung.
Clausen et al Dovepress
submit your manuscript | www.dovepress.com
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At a median follow-up time of 7.9 years (IQR 5.3 −10.8),
1820 events had occurred. Five-year OS was 79% (95% CI
76–82) for patients with Hgb above the mean, 71% (95% CI
68–73) for those with Hgb in the normal range but at or
below the mean, 54% (95% CI 51–57) for patients with Hgb
below the normal range to or at the transfusion threshold, and
37% (95% CI 32–42) for patients with Hgb below the trans-
fusion threshold (Figure 1).
The calculated crude and adjusted hazard ratios (HR)
are summarized in Table 2. Compared to patients with
Hgb above the mean, the other three groups in decreasing
order of Hgb levels had inferior OS (HR=1.23, 95% CI
1.01–1.49; HR=1.51, 95% CI 1.25–1.83; and HR=2.05
95% CI 1.65–2.56, respectively) after adjustment for sex,
NCCN-IPI, rituximab treatment, and comorbidity. Similar
results were observed for EFS (Table 2). In the model
with imputed values, accounting for missing information
for both exposure (n=32) and covariates (n=91), results
compared well to the results obtained without imputation
in both the crude and adjusted analysis (Table S1).
To estimate the Hgb association for selected subgroups,
we conducted analyses stratified on age, sex, and rituxi-
mab treatment (Table 3). Regarding age strata (≤60 vs >60
years), an association of lower Hgb concentrations with
inferior OS was observed in both strata but was more
prominent in patients above 60 years. Similarly, the asso-
ciation of lower Hgb levels and poorer OS was also
observed when stratifying for sex. Interestingly, this asso-
ciation was stronger in men (Table 3). To analyze the
influence on mortality of Hgb concentrations, considered
as a continuous variable, we used cubic splines with knots
at Hgb percentiles 5, 17.5, 50, 67.5, and 95 (Figure 2).
This showed that there was an almost linear association
of Hgb level and mortality below the 50th Hgb percentile
for both men and women. Notably, the cubic spline analysis
demonstrated that also a Hgb concentration in the lower end
of the normal range was associated with increased mortality.
In a further analysis, we stratified patients according to
whether they received rituximab in their primary treatment.
The association between Hgb levels and OS was present in
both treatment groups but was stronger for rituximab-trea-
ted patients. This observation finally, when stratifying
NCCN-IPI risk groups, the association of OS with Hgb
level was evident for both strata (low/low-intermediate vs
high-intermediate/high risk) (Figure 3).
Table 2 Crude And Adjusted HRs For OS According To Hgb For Both LYFO And MER
Hgb (LYFO) 5-year OS OS Unadjusted OS Multivariablea 5-Year EFS EFS Multivariable
N % 95% CI HR 95% CI N HR 95% CI % 95% CI HR 95% CI
>149/>134b 755 79 71–82 1.00 Ref. 739 1.00 Ref. 73 70–76 1.00 Ref.
134–149/118–134c 1132 71 68–73 1.52 1.26–1.85 1103 1.23 1.01–1.49 64 61–67 1.19 1.01–1.42
98–133/98–117c 1246 54 51–57 2.74 2.29–3.27 1211 1.51 1.25–1.83 49 46–52 1.46 1.23–1.73
<98 366 37 32–42 4.51 3.67–5.55 355 2.05 1.65–2.56 33 28–37 1.96 1.60–2.41
Hgb (MER)
>145/>135b 322 84 80–88 1.00 Ref. 322 1.00 Ref. 73 68–78 1.00 Ref.
135–144/120–134c 285 75 70–80 1.54 1.12–2.12 285 1.43 1.03–1.97 64 59–70 1.30 0.99–1.70
99–134/99–119c 482 65 60–69 2.31 1.75–3.06 482 1.53 1.14–2.05 51 47–56 1.32 1.03–1.68
<99 136 63 55–73 2.48 1.72–3.57 136 1.27 0.86–1.86 45 37–56 1.33 0.97–1.83
Notes: aAdjusted for NCCN-IPI, sex, comorbidity, and rituximab treatment, bHgb cutoff value for men/Hgb cutoff value for women, cHgb range for men/Hgb range for women.
Abbreviations: Hgb, pretreatment hemoglobin; OS, overall survival; EFS, event-free survival; ref, reference; HRs, hazard rate ratios.
Figure 1 Five-year OS for all patients, according to pretreatment Hgb subgroups
(training cohort).
Abbreviations: Hgb, pretreatment hemoglobin cutoff value or range in men/
pretreatment hemoglobin cutoff value or range in women; OS, overall survival.
Dovepress Clausen et al
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To illustrate the ability of Hgb levels to add prognos-
tic information to an established index such as the
NCCN-IPI, a comparison can be drawn to the NCCN-
IPI low-intermediate risk group. The 5-year OS reported
for this group in the original NCCN-IPI publication was
82%. In our cohort, the corresponding value for the same
risk group according to the four Hgb subsets (in decreas-
ing order of Hgb concentration) was 83% (95 CI%
78–87), 79% (95 CI% 74–82), 68% (95 CI% 63–73),
and 49% (95 CI% 34–62), respectively.
Patient Characteristics In The Validation
Dataset
Patients in the validation cohort had a median age of 63 years
(range 18–93 years: IQR 54–72), slightly younger than the
LYFO. In the MER, men were also more likely to have lower
Hgb at diagnosis and were otherwise comparable regarding
comorbidity, NCCN-IPI, and other clinical baseline character-
istics (Table S2). The NCCN-IPI risk group distribution was:
10.6% low, 39.3% low-intermediate, 40.8% intermediate-
high, and 9.2% high. All patients in the validation cohort
Table 3 Five-Year OS And Adjusted HRs Stratified On Selected Factors In The Discovery Cohort
5-Year OS Multivariable Modela
N % 95% CI N HR 95% CI
Women 1542 1507
134b 395 77 72–81 388 1.00 Ref.
118–134b 564 69 65–72 551 1.11 0.86–1.44
98–117b 407 58 53–62 395 1.24 0.95–1.62
<98 176 41 34–48 173 1.50 1.10–2.03
Men 1957 1901
>149b 360 83 78–86 330 1.00 Ref.
134–149c 568 73 69–76 552 1.39 1.02–1.89
98–133c 839 52 49–56 816 1.88 1.41–1.94
<98 190 34 27–41 182 2.85 2.05–3.96
<61 years 1291 1226
>149b/>134b 334 88 84–91 330 1.00 Ref.
134–149/118–134c 432 86 83–89 420 0.82 0.54–1.25
98–133/98–117c 417 71 66–75 409 1.25 0.84–1.86
<98 108 47 38–56 106 2.35 1.52–3.71
≥61 years 2208 2143
>149b/>134b 421 66 63–69 409 1.00 Ref.
134–149/118–134c 700 57 52–62 683 1.38 1.10–1.73
98–133/98–117c 829 55 47–62 802 1.70 1.36–2.12
<98 258 46 37–54 249 2.12 1.64–2.72
CHOP 883 865
>149b/>134b 207 73 67–79 206 1.00 Ref.
134–149/118–134c 284 65 59–70 275 1.07 0.76–1.49
98–133/98–117c 293 48 42–53 287 1.11 0.80–1.55
<98 99 28 20–37 97 1.64 1.12–2.40
R-CHOP 2616 2543
>149b/>134b 548 76 74–78 533 1.00 Ref.
134–149/118–134c 848 66 61–70 828 1.30 1.02–1.67
98–133/98–117c 953 65 58–71 924 1.73 1.37–2.19
<98 267 51 43–60 258 2.21 1.68–2.90
Notes: aAdjusted for NCCN-IPI, comorbidity, sex, and rituximab treatment except for factor stratified on. bHgb cutoff value for men/Hgb cutoff value for women, cHgb
range for men/Hgb range for women.
Abbreviations: Hgb, pretreatment hemoglobin; OS, overall survival; ref, reference; HR, hazard rate ratios.
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received immunochemotherapy with rituximab in combina-
tion with a CHOP/CHOP-like regimen. The same sex-related
differences in anemia occurrence were also found in the vali-
dation cohort (Figure S3A and B). Similar findings for OS
were obtained from the analysis of the validation cohort
(Table 2), both overall (Figure S4) and stratified by NCCN-
IPI (Figure S5), although the outcome of the lowest Hgb group
was better than in the LYFO. Compared to patients with Hgb
above the mean, the next two groups in decreasing order of
Hgb levels had inferior OS (HR=1.43, 95% CI 1.03–1.97 and
HR=1.53, 95% CI 1.14–2.05, respectively) after adjustment
for sex, NCCN-IP,I and any comorbidities, while the risk
estimate for the lowest Hgb levels was attenuated and not
statistically significant (HR=1.27, 95% CI 0.86–1.86).
In the MER cohort, 70% of the cases had COO data
available (Table S3). Patients with lower Hgb were more
likely to have a non-GCB signature (50%), while the
opposite was observed for patients with Hgb above mean
(25%). Overall, 35% of the patients were classified as
non-GCB.
Discussion
In this study of prospectively collected data, we found that
lower Hgb concentration was associated with increased
mortality both in the discovery cohort from LYFO and in
the validation cohort from the US. Most provocatively,
patients with Hgb below the mean but still within the
normal range also had inferior OS compared to the refer-
ence group (normal values at or above the mean).
Strengths of this study include the population-based
design through linkage of high-quality data from both regio-
nal and national registries, homogeneous treatments based on
national recommendations, and a near-complete follow-up.
Moreover, we were able to validate our findings in an inde-
pendent cohort of community-based participants. As in all
observational studies, some limitations have to be consid-
ered. We identified the patients using the LYFO register
which captures virtually every patient diagnosed with lym-
phoma in Denmark. A validation analysis of this registry
showed that the number of patients who escaped registration
was very low (1.6%) and primarily consisted of low-grade
lymphomas.14 With regard to the information on follow-up
time and vital status, accuracy was secured on the basis of the
daily updates performed by the Danish Civil Registration
System.23 Thus, selection bias in our discovery study cohort
is likely to be minor. In terms of potential misclassification of
Hgb values, a Scandinavian quality control study on Hgb
measurements from different Scandinavian laboratories,
including those relevant to the present study, found that all
values were within ±2% of the mean for all measurements.19
Regarding Hgb measurements in the MER, they were per-
formed as part of routine evaluation of a new lymphoma.
Furthermore, we were able to adjust for known prognostic
factors included in well-established international prognostic
Figure 2 Restricted cubic splines describing hazard rate ratios (___) and 95% CI (- - -) for 5-year mortality as a function of pretreatment Hgb concentration for (A) men and
(B) women, adjusted for NCCN-IPI, comorbidity, and rituximab treatment. Knots are placed at percentiles 5, 17.5, 50, 67.5, and 95.
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indices and, in addition to LYFO, we also had access to data
allowing us to adjust for comorbidity. A parameter, which
could not be elucidated reliably in the LYFO, was the COO.
In the MER, the Hans classifier was used to determine COO,
and non-GCB patients overall had lower Hgb than those with
GCB phenotype. Two studies have not found an association
between Hgb and COO, which might be explained by lack of
power to detect a difference.
In previous reports, anemia was found at variable fre-
quencies (34%–77%) among patients with DLBCL.4–7,34 In
contrast to these studies, where Hgb concentrations were
dichotomized (anemic vs nonanemic), we examined Hgb
concentrations across the range of values both within the
normal range and at two levels of anemia (i.e., at or above
and below transfusion threshold). Through this approach, we
demonstrated a pattern of association between decreasing
pretreatment Hgb concentrations and increased mortality in
the study population. The underlying explanation for this
association is not clear. The same applies to the observed
sex-related differences, where anemia seemed to have a
stronger adverse impact on men. The latter cannot be
explained as being related to comorbidity since the preva-
lence of mild and severe comorbidity was similar for men
and women. Other factors such as body mass index and
Figure 3 Five-yearOS for low vs highNCCN-IPI risk groups (A) and according to hemoglobin (Hgb) subgroups in R-CHOP/R-CHOP-like treated patients (B andC). [training cohort].
Abbreviations: Hgb, cutoff value or range in men/Hgb cutoff value or range in women; OS, overall survival; NCCN-IPI, National Comprehensive Cancer Network
International Prognostic Index.
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menopausal status may play a role in this context. Age
imbalances cannot explain this either, since men had a
lower median age (64 vs 66 years). A higher impact of
treatment-related toxicity and a possible hypoxia-induced
lower treatment sensitivity, for example in cases with bulky
disease, may also be considered as possible contributing
factors. Although not previously described in lymphoma,
the latter consideration is well recognized in solid tumors
such as head-and-neck cancer.35 Furthermore, the additional
prognostic information of hemoglobin concentration found
in the present study may suggest the existence of a specific
biology behind the not otherwise specified DLBCL-asso-
ciated pretreatment anemia. For instance, extranodal disease
was present in 17% vs 59% of patients in the highest vs
lowest Hgb group, an observation not explained by bone
marrow infiltration alone (6% vs 29%). The causality of
this observation cannot be determined within the present
study, but could for example be either: 1) extranodal lym-
phoma leads to anemia via inflammation or 2) the biology of
a specific subgroup of DLBCL increases the likelihood of
dissemination to extra-nodal sites and anemia merely repre-
sents an epiphenomenon, both manifestations could also be
mediated by inflammation.36
In the light of an increasing number of experimental
treatment options in both fit and frail DLBCL patients, the
allocation to risk-adapted treatment strategies is necessary
and it may be improved by the addition of an easily
accessible and broadly available parameter such as Hgb.
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